25 Jul
Infliximab is a chimeric immunoglobulin (IgG1 kappa) targeting tumor necrosis factor-alpha (TNF-a), and is currently used for
the treatment of multiple inflammatory conditions. Infliximab binds to soluble TNF-a and transmembrane homotrimers.Testing for antibodies to infliximab (ATI) is recommended if there is a loss of response to infliximab.